Effect of Cannabidiol (CBD) on Patients with Psychiatric Disorders: a Systematic Review
Keywords:
Psychiatric patients, Cannabidiol(CBD), Medical treatment, CannabisAbstract
Introduction: Cannabis is a plant that has a psychoactive effect. It has been used as a medicine since ancient times. The UK has used cannabis to treat depression. China has used cannabis and wine as an anesthetic. Marijuana has been used in India to suppress nerve pain, gout, rheumatoid arthritis, epilepsy, movement disorders, depression, and psychosis. Thailand classifies marijuana as a Category 5 drug under the Narcotic Drug Act1979, and medical marijuana was allowed in 2019 and is still rare in the treatment of medical psychiatric patients. The purpose of this study was to review the body of knowledge related to cannabis and psychiatric disorders.
Methods: A systematic review of related articles obtained from the electronic databases of Pub Med and Google Scholar. The study emphasized articles that have been published from 2002 to 2022. The reviewed articles were assessed for their quality using the research quality assessment form suggested by Heller RF, et al. (2008).
Results: According to the result, a total of 197 articles were published during the period, there were 9 articles that met the criteria of the research quality assessment form andwere associated with studies on the use of medicinal cannabis-containing drugs in psychiatric patients.
Conclusion: The use of cannabidiol or CBD in the treatment of psychiatric disorders including depression, schizophrenia, and insomnia in males and female adults and adolescents,. The articles revealed the positive therapeutic effect of cannabidiol or CBD since it could alleviate the symptoms of the disease. As a result, patients’symptoms were improved in high-risk groups, those with early symptoms, and those with psychiatric disorders. In addition, they revealed noside effects from the treatment using CBD.
Downloads
References
Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol. 2006;20(5):683-6.
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. Am J Psychiatry. 2018;175(3):225-31.
Edwards J, Elkins K, Hinton M, Harrigan S, Donovan K, Athanasopoulos O, et al. Randomized controlled trial of a cannabis‐focused intervention for young people with first‐episode psychosis. Acta Psychiatrica Scandinavica. 2006;114(2):109-17.
Amminger GP, Lin A, Kerr M, Weller A, Spark J, Pugh C, et al. Cannabidiol for at risk for psychosis youth: A randomized controlled trial. Early intervention in psychiatry. 2022;16(4):419-32.
Kayani S. Investigating views and opinions of using Cannabidiol (CBD) to relieve stress and insomnia. 2018.
Berger M, Li E, Amminger GP. Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. BMJ Case Reports CP. 2020;13(10):e235307.
Schoevers J, Leweke JE, Leweke FM. Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies. Current Opinion in Psychiatry. 2020;33(3):185-91.
Laczkovics C, Kothgassner OD, Felnhofer A, Klier CM. Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Neuropsychiatr. 2021;35(1):31-4.
Rouble AN, Tazkarji B. Is cannabidiol an effective treatment of anxiety in adults? Evidence-Based Practice. 2021;24(11):13-4.
ศ.พญ.สุวรรณา อรุณพงศ์ไพศาล พณเ. <การใช้สารสกัดกัญชาสำหรับผู้ป่วยที่มีปัญหาสุขภาพจิต>. วารสารกรมการแพทย์. 2562;44(1).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Singburi Hospital Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The published articles are copyrighted by Singburi Hospital.
The statements appearing in each article in this academic journal are the personal opinions of each author and are not related in any way to Singburi Hospital or other hospital personnel. Each author is solely responsible for all contents of their article. If there are any errors, each author alone will be responsible for their own article.
